Belamaf
(Belantamab)Phase 3Monoclonal antibody
GSKBelantamab is used to treat multiple myeloma, a type of blood cancer where abnormal plasma cells multiply in the bone marrow. It works by targeting and destroying cancer cells that have a specific protein on their surface.[1] Belamaf is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Belamaf is one of 219 biologic programs targeting AL amyloidosis. It is currently in Phase 3.
7
Indications
59
Total Trials
38
Active Trials
218
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma42 trials
Show 39 more trials
ART3 trials
Monotherapy2 trials
Dexamethasone2 trials
9 more indications
Relapsed/Refractory1 trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Not yet recruiting·—·Phase 2·NCT05874193·33 enrolled
Immune Thrombocytopenia1 trial
Lenalidomide1 trial
Amyloidosis1 trial
Autoimmune Disease1 trial
AL amyloidosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Belantamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]